Department of Pharmacology, SVKM\'S Dr. Bhanuben Nanavati College of Pharmacy, Mithibai Campus, Vile Parle (W), Mumbai-400056, India.
Endocr Metab Immune Disord Drug Targets. 2022;22(4):371-382. doi: 10.2174/1871530321666211124102837.
The most common liver diseases are fibrosis, alcoholic liver disease, nonalcoholic fatty disease, viral hepatitis, and hepatocellular carcinoma. These liver diseases account for approximately 2 million deaths per year worldwide, with cirrhosis accounting for 2.1% of the worldwide burden. The most widely used liver function tests for diagnosis are alanine transaminase, aspartate transaminase, serum proteins, serum albumin, and serum globulins, whereas antivirals and corticosteroids have been proven to be useful for the treatment of liver diseases. A major disadvantage of these diagnostic measures is the lack of specificity to a particular tissue or cell type, as these enzymes are common to one or more tissues. The major adverse effect of current treatment methods is drug resistance. To overcome these issues, interleukins have been investigated. The balance of these interleukins determines the outcome of an immune response. Interleukins are considered interesting therapeutic targets for the treatment of liver diseases. In this review, we summarize the current state of knowledge regarding interleukins in the diagnosis, treatment, and pathogenesis of different acute and chronic liver diseases.
To understand the role of interleukins in the assessment and treatment of different types of liver diseases.
A literature search was conducted using PubMed, Science Direct, and NCBI with the following keywords: Interleukins, Acute Liver Failure, Alcoholic Liver Disease, Non-Alcoholic Fatty Liver Disease, Liver Fibrosis, Hepatocellular Carcinoma, Inflammation, Liver injury, Hepatoprotective effect. Clinical trial data on these interleukins have been searched on Clinicaltrials.gov.
Existing literature and preclinical and clinical trial data demonstrate that interleukins play a crucial role in the pathogenesis of liver diseases.
Our findings indicate that IL-1, IL-6, IL-10, IL-17, IL-22, IL-35, and IL-37 are involved in the progression and control of various liver conditions via the regulation of cell signaling pathways. However, further investigation on the involvement of these interleukins is necessary for their use as a targeted therapy in liver diseases.
最常见的肝脏疾病包括纤维化、酒精性肝病、非酒精性脂肪性疾病、病毒性肝炎和肝细胞癌。这些肝脏疾病每年在全球导致约 200 万人死亡，其中肝硬化占全球负担的 2.1%。目前用于诊断的最广泛使用的肝功能测试包括丙氨酸转氨酶、天冬氨酸转氨酶、血清蛋白、血清白蛋白和血清球蛋白，而抗病毒药物和皮质类固醇已被证明对肝脏疾病的治疗有效。这些诊断措施的一个主要缺点是缺乏对特定组织或细胞类型的特异性，因为这些酶在一种或多种组织中都很常见。目前治疗方法的主要不良反应是耐药性。为了克服这些问题，已经研究了白细胞介素。这些白细胞介素的平衡决定了免疫反应的结果。白细胞介素被认为是治疗肝脏疾病的有趣治疗靶点。在这篇综述中，我们总结了白细胞介素在不同急性和慢性肝脏疾病的诊断、治疗和发病机制中的最新知识状态。
了解白细胞介素在评估和治疗不同类型肝脏疾病中的作用。
使用 PubMed、Science Direct 和 NCBI 进行文献检索，使用以下关键词：白细胞介素、急性肝衰竭、酒精性肝病、非酒精性脂肪性肝病、肝纤维化、肝细胞癌、炎症、肝损伤、肝保护作用。在 Clinicaltrials.gov 上搜索了这些白细胞介素的临床试验数据。
现有的文献和临床前及临床试验数据表明，白细胞介素在肝脏疾病的发病机制中起着至关重要的作用。
我们的研究结果表明，IL-1、IL-6、IL-10、IL-17、IL-22、IL-35 和 IL-37 通过调节细胞信号通路，参与各种肝脏疾病的进展和控制。然而，为了将这些白细胞介素用作肝脏疾病的靶向治疗，需要进一步研究它们的参与。
